These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 24236720)

  • 21. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
    Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
    J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New frontiers in the therapy of tuberculosis: fighting with the global menace.
    Chhabria M; Jani M; Patel S
    Mini Rev Med Chem; 2009 Apr; 9(4):401-30. PubMed ID: 19356120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status and future development of antitubercular chemotherapy.
    Kremer LS; Besra GS
    Expert Opin Investig Drugs; 2002 Aug; 11(8):1033-49. PubMed ID: 12150700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The significance of GlgE as a new target for tuberculosis.
    Kalscheuer R; Jacobs WR
    Drug News Perspect; 2010 Dec; 23(10):619-24. PubMed ID: 21180647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.
    Ntie-Kang F; Yong JN; Owono Owono LC; Sippl W; Megnassan E
    Curr Med Chem; 2014; 21(30):3466-77. PubMed ID: 25005178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
    Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on the chemistry and medicinal chemistry of novel antimycobacterial compounds.
    Branco FS; Pinto AC; Boechat N
    Curr Top Med Chem; 2013; 13(22):2808-49. PubMed ID: 24111907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review on various heterocyclic moieties and their antitubercular activity.
    Sharma S; Sharma PK; Kumar N; Dudhe R
    Biomed Pharmacother; 2011 Jul; 65(4):244-51. PubMed ID: 21715130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
    Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
    Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.
    Sacchettini JC; Rubin EJ; Freundlich JS
    Nat Rev Microbiol; 2008 Jan; 6(1):41-52. PubMed ID: 18079742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F; Ventura C; Santos S; Viveiros M
    Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review on anti-tuberculosis peptides: Impact of peptide structure on anti-tuberculosis activity.
    Yathursan S; Wiles S; Read H; Sarojini V
    J Pept Sci; 2019 Nov; 25(11):e3213. PubMed ID: 31515916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.